Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- REGULATORY NEWS IN BRIEF
April 9, 2007
- Takeda, CanBas to Jointly Develop Anticancer Treatment
April 9, 2007
- Takeda, LGLS to Collaborate to Develop Anti-Obesity Drugs
April 9, 2007
- Takeda Acquires Full Rights to R-851 from 3M
April 9, 2007
- BI Expects Double-Digit Growth Again in 2007: Chairman Dr Banchi
April 9, 2007
- Astellas Licenses Technology for Discovering hMAbs
April 9, 2007
- Antidiabetic Drug Market Predicted to Increase to ¥490 Billion in 2015
April 9, 2007
- R&D NEWS IN BRIEF
April 9, 2007
- Mochida to Distribute Remodulin in Japan
April 9, 2007
- Alfresa Aims to Build Nationwide Network for OTC Drugs: President Watanabe
April 9, 2007
- Asahi Kasei Licenses Eril to Eisai in South Korea
April 9, 2007
- Cook's Zenith AAA Endovascular Graft Reimbursed from April 1
April 9, 2007
- Kissei's MRs Provide Drug Safety Data on the Spot
April 9, 2007
- MEDICAL DEVICE NEWS IN BRIEF
April 9, 2007
- Alfresa Aims at 70% Share for Drugs for Narcolepsy with Modafinil
April 9, 2007
- Kobayashi Kako to Distribute Generics in Asian Countries
April 9, 2007
- Rep Track Survey: Anti-Allergy Drugs Enter Pollinosis Season
April 9, 2007
- GENERIC NEWS IN BRIEF
April 9, 2007
- Korosho Issues New Notifications to Accelerate Price Agreements
April 9, 2007
- Pfizer Enhances Sexual Harassment Measures in Response to Law Amendment
April 9, 2007
ページ
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…